Daré Bioscience, Inc. (NASDAQ:DARE ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants MarDee J. Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - CEO, President, Principal Financial Officer, Secretary & Director Operator Welcome to the conference call hosted by Daré Bioscience Therapeutics Company's Second Quarter 2025 Financial Results and to p...
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide ...
A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most
Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive
Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company's 2025 annual meeting of stockholders (the “Annual Meeting”) was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is nec...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.